No connection

Search Results

JAGX vs JNJ

JAGX
Jaguar Health, Inc.
BEARISH
Price
$0.37
Market Cap
$4.6M
Sector
Healthcare
AI Confidence
95%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
JAGX
--
JNJ
21.55
Forward P/E
JAGX
-0.06
JNJ
18.9
P/B Ratio
JAGX
-0.13
JNJ
7.03
P/S Ratio
JAGX
0.4
JNJ
6.09
EV/EBITDA
JAGX
-1.12
JNJ
17.81

Profitability

Gross Margin
JAGX
67.21%
JNJ
68.08%
Operating Margin
JAGX
-631.9%
JNJ
23.97%
Profit Margin
JAGX
0.0%
JNJ
28.46%
ROE
JAGX
--
JNJ
35.03%
ROA
JAGX
-61.46%
JNJ
8.68%

Growth

Revenue Growth
JAGX
-7.8%
JNJ
9.1%
Earnings Growth
JAGX
--
JNJ
48.6%

Financial Health

Debt/Equity
JAGX
--
JNJ
0.6
Current Ratio
JAGX
0.5
JNJ
1.03
Quick Ratio
JAGX
0.07
JNJ
0.69

Dividends

Dividend Yield
JAGX
--
JNJ
2.19%
Payout Ratio
JAGX
0.0%
JNJ
46.6%

AI Verdict

JAGX BEARISH

JAGX exhibits extreme financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a Quick Ratio of 0.07, suggesting it cannot meet short-term obligations. Despite a positive gross margin, the operating margin is catastrophic at -631.90%, and the stock has collapsed by 92.8% over the last year. The combination of declining revenue and consistent earnings misses points toward a high risk of insolvency.

Strengths
Positive Gross Margin (67.21%)
Low Price-to-Sales ratio (0.40)
Recent reduction in the magnitude of quarterly losses
Risks
Severe liquidity risk (Quick Ratio 0.07)
Negative equity (Price/Book -0.13)
Catastrophic operating losses (-631.90% margin)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

JAGX vs JNJ: Head-to-Head Comparison

This page compares Jaguar Health, Inc. (JAGX) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile